Read it again Hamilr. It was not me and they did offer a position. My point is they waste money needlessly on fedexing late checks to recruits.
I tried to call investor relations a few weeks ago and got no call back. I called customer service twice today. the automated answering machine answers the phones but directs you to customer service where "no agents are available" to take your order and asks that you leave a message. The website is up but does not take orders. It looks like this company has gone out of business.
"The Medicines and Healthcare products Regulatory Agency (MHRA) jointly with European healthcare product regulators of member states has been informed of the suspension of the CE certificate for all medical devices made by the Brazilian manufacturer Silimed. The German notified body, has recently carried out an inspection of the manufacturing plant in Brazil and established that the surfaces of some devices were contaminated with particles."
They will have hard time trying to determine the source of particles, what they are made of, when implants were first contaminated and how many implants may be contaminated etc. Being cautious they will recall the implants that they can and have to pay for health monitoring for the patients who are not explanted. I doubt this mess will be resolve very quickly.
No scamming, just an investor stating the facts. If you are a "strong sell" then why don't you sell and stop wasting your time on this board - or maybe you are a scammer. hmmmm?
sales are on a run rate of nearly $20M. Its hard to find growth like this at a revenue multiple below 1 times. I picked up 2,000 shares yesterday at $2.07 .
I read the S-1 that they did not have legal proceedings.
It may look like the CEO bought 100,000 shares at $6.34 but the board gave him 200,000 shares of stock as incentives so he is getting 300,000 shares for the price of 100,000; that is a lot of leverage. The board is targeting CEO compensation at $4.7 million this year per the proxy. I wish the company made as much profit as the CEO.
40 million shares at 50 cents is only $20 million. they are burning $10 million a quarter. This does not give them a lot of breathing room. They had 12.5 million in cash plus 20 = $32.5 may 3-4 quarters worth. If Sales double from 12-24 million, the additional 12 million will give them about 40% cash yield or 5 million in cash. They need to lower the expenses as well are increase sales or we will be doing another dilutive offering this time next year.
Many of you seem to feel the Valeant bid is inadequate but the stock was trading in the $130s at the time and you were not bidding it up to $180. Maybe we shareholders did not know the secret value of AGN but surely we do now, yet the stock drops daily from the inadequate offer from Valeant to an even lower price. Hmmm...If you all think it is worth $200 a share then you should be buying this grand bargain.
Now you may love Mr. Pyott but he needs to earn a return for all shareholders even the recent ones and the ones he may not actually like; if someone else thinks they can do better, they need to pay up and they get their right to choose. You may like Mr. Pyott, trust me he will make lots of money either way, and land at a new company where maybe you can take the ride all over again. Who knows maybe Valeant will make him the CEO! BTW the dividend is an insulting low for all the non-GAAP profit AGN reports.
I was first introduced to Thoratec in early 2009 and was impressed. the stock was around $33. Imagine my surprise when an ex-director mentioned it today at lunch and the stock was still at $33! Did I slip into a time warp? I wondered how such a great technology could produce not shareholder returns in over 5 years, I had to look to see if the same CEO was at the helm. Yep it sure looks like it. Sometimes you really have to wonder what it takes to get a board off of its dead duff and do something.
Marcy l'Etoile, France - April 23, 2014
FIRST-QUARTER 2014 BUSINESS REVIEW FIOR BIOMERIEUX
• Up 7.9%, including BioFire and at constant exchange rates
• Up 4.1% like-for-like*, in line with the target for the year
o Continued stabilization in Western Europe, up 1.4%*
o Sustained solid growth in North America, up 5.4%*
• Up 3.3%, on a reported basis
2014 objective of 3 - 5% organic sales growth maintained
Integration of BioFire effectively underway
Alexandre Mérieux, Chief Executive Officer, said: “During the first quarter of 2014, bioMérieux's sales rose by 4.1% at constant exchange rates and scope of consolidation, in line with our target for the year, and by 7.9% after consolidating the sales from BioFire, acquired in mid-January 2014. Sales continued to trend upwards in Europe and North America. BioFire’s FilmArray® system pursued its rapid expansion, with 55 new instruments installed since the company’s acquisition. In addition, we continued to roll out VIDAS® 3, whose application for approval was filed with Chinese authorities, and we prepared for the forthcoming market launch of our innovative new clinical microbiology platforms. Lastly, in line with our strategic plan, we are deploying a new operating organization designed to effectively meet public health challenges and our customers' needs around the world”.
It looks like the Douglas Ingram, president sold 98.8% of his holdings (84,000 shares) on Feb 14th and David Pyott, CEO sold 60% of his shares (252,000 shares) two days earlier. Hardly makes me feel good about holding my shares.
If your take is the money is dead, you should sell and put the cash in a savings account at wells fargo. I hear them are paying 2-3 % below the inflation rate. It is pretty hard to grow sales at a 100% clip and get new accounts trained properly. That said, they need to work on the gross margin, revenue is not much good if there is no margin to cover overhead.
UPDATE 1-FDA OKs Merck OTC version of overactive bladder drug
Fri Jan 25, 2013 12:40pm EST
Jan 25 (Reuters) - U.S. health regulators approved Merck & Co's nonprescription version of Oxytrol to treat overactive bladder in women ages 18 and older, the agency said on Friday.
The U.S. Food and Drug Administration said the over-the-counter version of Oxytrol would be available for women only and that the drug remained available to men by prescription.
Overactive bladder, which affects an estimated 33 million Americans, is a condition in which the bladder squeezes too often or without warning. Symptoms include leaking urine, feeling a sudden and urgent need to urinate, and frequent urination.
Oxytrol for Women is a patch that contains oxybutynin, a medicine that helps relax the bladder muscle, and is designed to be applied to the skin every four days, the FDA said.
Oxybutynin belongs to a class of drugs known as anticholinergics. Pfizer Inc's Detrol is the market leader in the class with annual sales of about $700 million.
Oxytrol will be the first drug in the class to be sold over the counter. Merck licensed exclusive rights to sell OTC Oxytrol from Actavis Inc, the generic drugmaker formerly known as Watson Pharmaceuticals.
Merck said it expected the OTC patch to be available in the fall.
The FDA decided to approve the OTC version of the Merck drug, based on the results of nine studies of women that demonstrated that consumers can understand the information on the label, properly determine whether the product is right for them, and use the drug appropriately, the agency said.
Last week, the FDA approved the popular wrinkle treatment Botox from Allergan Inc to treat overactive bladder in people who cannot tolerate drugs from the class to which Oxytrol belongs or are not helped by these medications.